Global Infertility Drugs Market to Reach USD 6.3 Billion by 2033, Propelled by the Rising Incidences of Infertility and Miscarriage

December 25, 2024 | Healthcare

The latest report by IMARC, titled “Infertility Drugs Market Report by Drug Class (Gonadotropin, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Biguanides, and Others), Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), End User (Male, Female), and Region 2025-2033”, finds that the global infertility drugs market reached a value of USD 4.1 Billion in 2024. Infertility drugs refer to medications prescribed to treat infertility and improve the reproductive health of an individual. They are either injected or consumed orally. Some of the commonly available infertility drugs include aromatase inhibitors, gonadotrophins, selective estrogen receptor modulators (SERMs), ovulatory stimulants, biguanides, tricyclic antidepressants, and dopamine agonists. These drugs assist by stimulating ovulation and follicle development of the ovary in women while restoring testosterone levels in men and improving the quality of their sperm. In recent years, infertility drugs have gained momentum among couples who are unable to conceive.


Global Infertility Drugs Market Trends:

One of the primary factors driving the market is the rising incidences of infertility and miscarriage. Additionally, the increasing number of individuals diagnosed with thyroid, polycystic ovarian syndrome (PCOS), diabetes, and menopausal disorders due to the hectic lifestyle and stress is creating a positive market outlook. Other than this, the declining fertility rates due to unhealthy habits, such as a rise in the consumption of drugs, alcohol and smoking, are leading to an increase in the adoption rate of these medications. Besides this, extensive research and development (R&D) activities to introduce infertility drugs with better efficacy, lower dosage requirement, and lesser side effects are creating a positive market outlook. Other growth-inducing factors include enhancing health infrastructure, increasing consumer expenditure, rising demand for generic medicines, rapid urbanization, and technological upgradations. Looking forward, IMARC Group expects the market value to reach USD 6.3 Billion by 2033, expanding at a CAGR of 4.49% during the forecast period (2025-2033).


Market Summary:

  • Based on the drug class, the market has been divided into gonadotropin, aromatase inhibitors, selective estrogen receptor modulators (SERMs), biguanides, and others.
  • On the basis of the route of administration, the market has been segregated into oral, intravenous, subcutaneous, and intramuscular.
  • Based on the distribution channel, the market has been segmented into hospital pharmacies, retail pharmacies, and others.
  • On the basis of the end user, the market has been bifurcated into males and females.
  • Region-wise, the market has been classified into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
  • The competitive landscape of the market has also been analyzed, with some of the key players being Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., and Theramex HQ UK Limited.

Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Drug Class, Route of Administration, Distribution Channel, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Theramex
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter : @imarcglobal

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Infertility Drugs Market to Reach USD 6.3 Billion by 2033, Propelled by the Rising Incidences of Infertility and Miscarriage
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials